X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2605) 2605
Book Review (188) 188
Publication (121) 121
Newsletter (38) 38
Conference Proceeding (25) 25
Book Chapter (3) 3
Magazine Article (2) 2
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (2293) 2293
humans (2001) 2001
male (1534) 1534
female (1524) 1524
busulfan - administration & dosage (1305) 1305
busulfan (1198) 1198
hematology (1196) 1196
adult (1143) 1143
transplantation (1116) 1116
middle aged (1012) 1012
oncology (947) 947
adolescent (796) 796
immunology (693) 693
child (598) 598
bone-marrow-transplantation (588) 588
transplantation conditioning - methods (558) 558
cyclophosphamide (518) 518
stem cells (513) 513
cyclophosphamide - administration & dosage (512) 512
aged (499) 499
antineoplastic combined chemotherapy protocols - therapeutic use (483) 483
child, preschool (470) 470
hematopoietic stem cells (463) 463
treatment outcome (460) 460
hematopoietic stem cell transplantation (455) 455
transplantation, homologous (455) 455
busulfan - therapeutic use (437) 437
animals (433) 433
busulfan - adverse effects (426) 426
chemotherapy (400) 400
stem-cell transplantation (373) 373
bone marrow transplantation (365) 365
retrospective studies (358) 358
vidarabine - analogs & derivatives (343) 343
infant (328) 328
children (322) 322
combined modality therapy (316) 316
pharmacokinetics (314) 314
hematopoietic stem cell transplantation - methods (313) 313
disease-free survival (304) 304
leukemia (288) 288
transplantation conditioning (284) 284
total-body irradiation (283) 283
cancer (266) 266
young adult (263) 263
busulfan - pharmacokinetics (262) 262
versus-host-disease (261) 261
health aspects (260) 260
survival analysis (258) 258
therapy (253) 253
dosage and administration (252) 252
risk factors (252) 252
hematopoietic stem cell transplantation - adverse effects (247) 247
bone-marrow transplantation (246) 246
transplantation, autologous (246) 246
stem cell transplantation (245) 245
survival rate (245) 245
vidarabine - administration & dosage (245) 245
care and treatment (244) 244
mice (244) 244
research (237) 237
follow-up studies (223) 223
fludarabine (217) 217
graft vs host disease - prevention & control (216) 216
toxicity (212) 212
transplantation conditioning - adverse effects (209) 209
hematology, oncology and palliative medicine (208) 208
bone marrow (206) 206
analysis (201) 201
melphalan - administration & dosage (201) 201
recurrence (199) 199
time factors (198) 198
busulfan - pharmacology (193) 193
dose-response relationship, drug (190) 190
pharmacology & pharmacy (187) 187
antineoplastic combined chemotherapy protocols - administration & dosage (186) 186
abridged index medicus (185) 185
acute myeloid-leukemia (182) 182
whole-body irradiation (182) 182
immunosuppressive agents - administration & dosage (180) 180
pediatrics (180) 180
remission induction (174) 174
leukemia, myeloid, acute - therapy (168) 168
mortality (166) 166
cyclophosphamide - therapeutic use (164) 164
antineoplastic agents, alkylating - administration & dosage (163) 163
antineoplastic combined chemotherapy protocols - adverse effects (163) 163
etoposide - administration & dosage (159) 159
busulfan - analogs & derivatives (155) 155
graft vs host disease - etiology (155) 155
high-dose busulfan (155) 155
melphalan (151) 151
cyclophosphamide - adverse effects (150) 150
intravenous busulfan (145) 145
myeloablative agonists - administration & dosage (143) 143
drug administration schedule (142) 142
prospective studies (139) 139
survival (139) 139
hematologic neoplasms - therapy (138) 138
prognosis (138) 138
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2484) 2484
Japanese (40) 40
German (27) 27
French (21) 21
Russian (21) 21
Chinese (18) 18
Spanish (16) 16
Polish (11) 11
Danish (3) 3
Czech (2) 2
Hungarian (2) 2
Italian (1) 1
Korean (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Blood, ISSN 0006-4971, 02/2015, Volume 125, Issue 9, pp. 1403 - 1410
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2013, Volume 19, Issue 1, pp. 117 - 122
Abstract Fifty patients with high-risk hematologic malignancies, underwent an unmanipulated haploidentical bone marrow transplantation (BMT), followed by... 
Hematology, Oncology and Palliative Medicine | Haploidentical transplantations | Acute leukemia | HLA | Posttransplantation cyclophosphamide | Allogeneic stem cell transplant | MORTALITY | IMMUNOLOGY | RECIPIENTS | VERSUS-HOST-DISEASE | TRANSPLANTATION | REDUCED-INTENSITY | ACUTE-LEUKEMIA | HIGH-RISK | HAPLOTYPE | OUTCOMES | STEM-CELL TRANSPLANTATION | HEMATOLOGY | BLOOD | Hematologic Neoplasms - therapy | Whole-Body Irradiation | Cyclophosphamide - administration & dosage | Follow-Up Studies | Myeloablative Agonists - adverse effects | Thiotepa - administration & dosage | Hematologic Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - administration & dosage | Busulfan - administration & dosage | Cyclophosphamide - adverse effects | Transplantation, Homologous | Graft vs Host Disease - mortality | Antineoplastic Agents - adverse effects | Bone Marrow Transplantation | Adult | Female | Retrospective Studies | Graft vs Host Disease - etiology | Immunosuppressive Agents - administration & dosage | Acute Disease | Busulfan - adverse effects | Vidarabine - adverse effects | Survival Rate | Vidarabine - analogs & derivatives | Disease-Free Survival | Adolescent | Myeloablative Agonists - administration & dosage | Graft vs Host Disease - prevention & control | Immunosuppressive Agents - adverse effects | Aged | Vidarabine - administration & dosage | Transplantation Conditioning | Chronic Disease | Thiotepa - adverse effects | Antimitotic agents | Pneumonia | Cyclophosphamide | Bacterial pneumonia | Mortality | Bone marrow | Transplantation | Antineoplastic agents | Cancer | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 10/2009, Volume 27, Issue 30, pp. 5001 - 5007
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2015, Volume 33, Issue 35, pp. 4167 - 4175
Journal Article
Cancer, ISSN 0008-543X, 08/2017, Volume 123, Issue 16, pp. 3073 - 3079
To the authors’ knowledge, the optimal approach to consolidative therapy for patients with primary central nervous system lymphoma in first complete remission... 
busulfan | high‐dose chemotherapy | primary central nervous system lymphoma (PCNSL) | autologous stem cell transplantation (ASCT) | cyclophosphamide | thiotepa | high-dose chemotherapy | PRIMARY CNS LYMPHOMA | 1ST-LINE TREATMENT | INTENSIVE CHEMOTHERAPY | IMMUNOCHEMOTHERAPY | CHEMOIMMUNOTHERAPY | METHOTREXATE | PHASE-II | WHOLE-BRAIN RADIOTHERAPY | CYTARABINE | THERAPY | ONCOLOGY | Cyclophosphamide - administration & dosage | Follow-Up Studies | Thiotepa - administration & dosage | Bacterial Infections - etiology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Transplantation, Autologous | Busulfan - administration & dosage | Lymphoma - therapy | Dacarbazine - analogs & derivatives | Adult | Female | Retrospective Studies | Dacarbazine - administration & dosage | Kaplan-Meier Estimate | Central Nervous System Neoplasms - therapy | Remission Induction | Cytarabine - administration & dosage | Rituximab - administration & dosage | Disease-Free Survival | Stem Cell Transplantation - methods | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mucositis - etiology | Methotrexate - administration & dosage | Aged | Temozolomide | Transplantation Conditioning | Stem Cell Transplantation - adverse effects | Chemotherapy | Usage | Care and treatment | Nervous system cancer | Thiotepa | Stem cells | Dosage and administration | Transplantation | Busulfan | Radiotherapy | Cancer | Brain | Toxicity | Central nervous system | Stem cell transplantation | Nervous system | Institutions | Confidence intervals | Cytarabine | Consolidation | Remission | Bacteria | Diagnosis | Conditioning | Methotrexate | Age | Autografts | Mucositis | Rituximab | Radiation therapy | Patients | Survival | Disease control | Lymphoma | Amplification | Cyclophosphamide | Lymphomas | Index Medicus | Abridged Index Medicus
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2016, Volume 23, Issue 3, pp. S403 - S403
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 4, pp. 500 - 514
Journal Article
Bone Marrow Transplantation, ISSN 0268-3369, 12/2011, Volume 46, Issue 12, pp. 1510 - 1518
This retrospective analysis evaluated 51 children (0.7-17 years; median eight) with high-risk or advanced hematological malignancies, including 18 (35%)... 
childhood hematological malignancies | preparative regimen | allogeneic hematopoietic SCT | Treosulfan | INTRAVENOUS TREOSULFAN | RISK-FACTORS | BONE-MARROW-TRANSPLANTATION | ACUTE MYELOID-LEUKEMIA | IMMUNOLOGY | I DOSE-ESCALATION | NONMALIGNANT DISEASES | TRANSPLANTATION | ONCOLOGY | HEPATIC VENOOCCLUSIVE DISEASE | ACUTE LYMPHOBLASTIC-LEUKEMIA | QUALITY-OF-LIFE | STEM-CELL TRANSPLANTATION | HEMATOLOGY | Hematologic Neoplasms - therapy | Busulfan - analogs & derivatives | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Hematologic Neoplasms - mortality | Humans | Child, Preschool | Etoposide - administration & dosage | Infant | Male | Survival Rate | Vidarabine - analogs & derivatives | Antineoplastic Agents, Alkylating - administration & dosage | Busulfan - administration & dosage | Transplantation, Homologous | Disease-Free Survival | Melphalan - administration & dosage | Adolescent | Female | Retrospective Studies | Vidarabine - administration & dosage | Transplantation Conditioning | Child | Carmustine - administration & dosage | Antimitotic agents | Complications and side effects | Care and treatment | Patient outcomes | Dosage and administration | Transplantation | Acute lymphocytic leukemia | Research | Antineoplastic agents | Hematopoietic stem cells | Index Medicus
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2011, Volume 17, Issue 6, pp. 893 - 900
Although a combination of i.v. busulfan (Bu) and fludarabine (Flu) is a safe, reduced-toxicity conditioning program for acute myelogenous... 
Hematology, Oncology and Palliative Medicine | AML | Allogeneic | Stem Cell Transplantation | Fludarabine | CML | IV Busulfan | Clofarabine | MDS | TOTAL-BODY IRRADIATION | CHRONIC MYELOGENOUS LEUKEMIA | PREPARATIVE REGIMEN | BONE-MARROW-TRANSPLANTATION | IMMUNOLOGY | VERSUS-HOST-DISEASE | TRANSPLANTATION | ADULT ACUTE-LEUKEMIA | HEPATIC VENOOCCLUSIVE DISEASE | DAILY INTRAVENOUS BUSULFAN | TERM-FOLLOW-UP | STEM-CELL TRANSPLANTATION | HEMATOLOGY | Injections, Intravenous | Humans | Middle Aged | Drug Resistance, Neoplasm | Male | Antineoplastic Agents - administration & dosage | Leukemia, Myeloid, Acute - immunology | Busulfan - administration & dosage | Transplantation, Homologous | Arabinonucleosides - administration & dosage | Graft vs Host Disease - mortality | Female | Adenine Nucleotides - administration & dosage | Immunosuppressive Agents - administration & dosage | Leukemia, Myeloid, Acute - therapy | Rabbits | Drug Administration Schedule | Leukemia, Myeloid, Acute - pathology | Hematopoietic Stem Cell Transplantation | Vidarabine - analogs & derivatives | Remission Induction | Drug Synergism | Leukemia, Myeloid, Acute - mortality | Animals | Tacrolimus | Survival Analysis | Cell Line, Tumor | Myeloablative Agonists - administration & dosage | Graft vs Host Disease - prevention & control | Antilymphocyte Serum | Vidarabine - administration & dosage | Transplantation Conditioning | Index Medicus | Allogeneic Stem Cell Transplantation
Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 383, Issue 9915, pp. 436 - 448
Summary Background In chronic granulomatous disease allogeneic haemopoietic stem-cell transplantation (HSCT) in adolescents and young adults and patients with... 
Internal Medicine | NADPH OXIDASE | MEDICINE, GENERAL & INTERNAL | EXCELLENT SURVIVAL | IN-VITRO | UNRELATED DONOR | BONE-MARROW-TRANSPLANTATION | EUROPEAN EXPERIENCE | INTRAVENOUS BUSULFAN | RECONSTITUTION | NONMALIGNANT DISEASES | CHILDREN | Transplantation Chimera - physiology | Prospective Studies | Humans | Child, Preschool | Infant | Treatment Outcome | Granulomatous Disease, Chronic - therapy | Vidarabine - analogs & derivatives | Alemtuzumab | Antilymphocyte Serum - administration & dosage | Busulfan - administration & dosage | Young Adult | Antibodies, Monoclonal, Humanized - administration & dosage | Adolescent | Adult | Graft vs Host Disease - prevention & control | Vidarabine - administration & dosage | HLA Antigens | Hematopoietic Stem Cell Transplantation - methods | Transplantation Conditioning - methods | Drug Therapy, Combination | Graft Survival - drug effects | Child | Immunosuppressive Agents - administration & dosage | Granuloma | Care and treatment | Histocompatibility antigens | Patient outcomes | HLA histocompatibility antigens | Stem cells | Transplantation | Identification and classification | Bone marrow | Teenagers | Transplants & implants | Mortality | Index Medicus | Abridged Index Medicus | Pediatrics | Immunologi inom det medicinska området | Pediatrik | hematopoietisk stamcellstransplantation | chronic granulomatous disease | Immunology in the medical area
Journal Article
Cancer, ISSN 0008-543X, 01/2015, Volume 121, Issue 2, pp. 226 - 233
Using high‐dose systemic rituximab may allow higher concentrations to penetrate the central nervous system. This article presents a phase 2 trial combining... 
busulfan | central nervous system (CNS) lymphoma | thiotepa | cyclophosphamide (TBC) | rituximab | autologous transplant | Rituximab | Busulfan | Autologous transplant | Thiotepa | Central nervous system (CNS) lymphoma | Cyclophosphamide (TBC) | PRIMARY CNS LYMPHOMA | 1ST-LINE TREATMENT | INTENSIVE CHEMOTHERAPY | INTRAOCULAR LYMPHOMA | WHOLE-BRAIN RADIOTHERAPY | CEREBROSPINAL-FLUID | STUDY-GROUP DSHNHL | ONCOLOGY | RECURRENT PRIMARY CNS | CONSOLIDATING RADIOTHERAPY | MARROW-TRANSPLANTATION | Cyclophosphamide - administration & dosage | Thiotepa - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Central Nervous System Neoplasms - surgery | Male | Transplantation, Autologous | Lymphoma, Non-Hodgkin - surgery | Busulfan - administration & dosage | Massachusetts | Adult | Female | Transplantation Conditioning - methods | Lymphoma, Non-Hodgkin - drug therapy | Drug Administration Schedule | Induction Chemotherapy - methods | Central Nervous System Neoplasms - therapy | Cytarabine - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Lymphoma, Non-Hodgkin - therapy | Aged | Hematopoietic Stem Cell Transplantation - methods | Infusions, Intravenous | Central Nervous System Neoplasms - drug therapy | Autografts | Cyclophosphamide | Care and treatment | Analysis | Stem cells | Dosage and administration | Transplantation | Non-Hodgkin's lymphomas | Diagnosis | Health aspects | Index Medicus | Abridged Index Medicus
Journal Article
Cancer, ISSN 0008-543X, 02/2015, Volume 121, Issue 4, pp. 562 - 569
The reduced toxicity regimen based on a busulfan dose of 130 mg/m 2 /day intravenously for 3 days, fludarabine at a dose of 30 mg/m 2 /day for 5 days, and... 
intravenous busulfan | prospective trial | allogeneic stem cell transplantation | submyeloablative conditioning | reduced‐intensity conditioning | Reduced-intensity conditioning | Allogeneic stem cell transplantation | Submyeloablative conditioning | Intravenous busulfan | Prospective trial | MORTALITY | BONE-MARROW-TRANSPLANTATION | THYMOGLOBULIN | ACUTE MYELOID-LEUKEMIA | reduced-intensity conditioning | VERSUS-HOST-DISEASE | INTENSITY PREPARATIVE REGIMEN | PHARMACOKINETICS | ONCOLOGY | MATCHED UNRELATED DONORS | HEMATOLOGIC MALIGNANCIES | STANDARD | Hematologic Neoplasms - therapy | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antilymphocyte Serum - administration & dosage | Busulfan - administration & dosage | Transplantation, Homologous | Adult | Female | Transplantation Conditioning - methods | Immunosuppressive Agents - administration & dosage | Antilymphocyte Serum - adverse effects | Busulfan - adverse effects | Drug Administration Schedule | Risk Factors | Vidarabine - adverse effects | Kaplan-Meier Estimate | Hematopoietic Stem Cell Transplantation | Vidarabine - analogs & derivatives | Hematologic Neoplasms - surgery | Disease-Free Survival | Hematologic Neoplasms - drug therapy | Immunosuppressive Agents - adverse effects | Vidarabine - administration & dosage | Infusions, Intravenous | Myeloblastic leukemia | Fludarabine | Patient outcomes | Stem cells | Dosage and administration | Transplantation | Busulfan | Research | Drug therapy | Antithymocyte globulin | Index Medicus | Abridged Index Medicus
Journal Article